Cem Akin - Concepedia

Author

Cem Akin

University of Michigan ORCID

Also Known As

Akin C., Akin Cem, Akin, C., Akin, Cem, C Akin, C. Akin, C. Akın, C. V. Akin, CEM AKIN, Carl D. Akin

406

Publications

18.7K

Citations

H-Index

Concepts

All Affiliations

University of Michigan National Institute of Allergy and Infectious Diseases National Institutes of Health Brigham and Women's Hospital Medical University of Vienna

About

Cem Akin is an author at University of Michigan specializing in medicine, immunology, and allergy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	43	3.1K
2	Allergy	16	22	1.2K
3	Allergy Medicine	4	4	87
4	Health Sciences	2	2	188
5	Public Health	1	1	14

Cem Akin

Publications

8.9K

Citations

H-Index

Page 1

	Year	Citations
Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal Peter Valent, Cem Akin, Michel Arock, International Archives of Allergy and Immunology	2011	623
Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI Arnold S. Kirshenbaum, Cem Akin, Yalin Wu, Leukemia Research Cell TherapyMedicineMast Cell DisorderImmunologyStem Cell Research	2003	501
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis Jason Gotlib, Hanneke C. Kluin‐Nelemans, Tracy I. George, New England Journal of Medicine	2016	465
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations Yongsheng Ma, Shan Zeng, Dean D. Metcalfe, Blood	2002	447
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness Amy D. Klion, Pierre Noël, Cem Akin, Blood	2003	388
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib Cem Akin, Gerard Fumo, Akif Selim Yavuz, Blood	2003	356
Mast cell activation syndrome: Proposed diagnostic criteria Cem Akin, Peter Valent, Dean D. Metcalfe Journal of Allergy and Clinical Immunology Autoimmune DiseaseMast Cell DisorderImmunologyHistopathologyAutoimmunity	2010	321
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis Neil P. Shah, Francis Y. Lee, Roger Luo, Blood	2006	272
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome Amy D. Klion, Jamie Robyn, Cem Akin, Blood	2003	240
Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis Cem Akin, Linda M. Scott, Can Naci Kocabaş, Blood	2007	235

Page 1